2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
19 déc. 2019 13h14 HE | Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
07 nov. 2019 16h00 HE | Capricor Therapeutics, Inc.
Provides Update on End of Phase Type-B Meeting with FDA Positive Data from the HOPE-2 Clinical Trial Presented at World Muscle Society To Host Conference Call and Webcast Today at 4:30 p.m....
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)
21 oct. 2019 09h25 HE | Capricor Therapeutics, Inc.
Call Scheduled for Thursday, October 24th at 10:30am Eastern Time LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company...